Nora Therapeutics

About:

Nora Therapeutics is a specialty biopharmaceutical company developing therapeutics to address clinical unmet needs in reproductive medicine.

Website: http://www.noratherapeutics.com

Top Investors: Novo Holdings, Vivo Capital, Rho Ventures, Burrill & Company, Prospect Venture Partners

Description:

Nora Therapeutics is a specialty biopharmaceutical company focused on developing therapeutics to address clinical unmet needs in reproductive medicine. Nora’s lead compound, NT100, is a novel treatment being studied to improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful in vitro fertilization (IVF) procedures. NT100 is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract. NT100’s mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance.

Total Funding Amount:

$36.8M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Palo Alto, California, United States

Founded Date:

2007-01-01

Contact Email:

info(AT)noratherapeutics.com

Founders:

Chris McClain

Number of Employees:

11-50

Last Funding Date:

2014-04-17

IPO Status:

Private

Industries:

© 2025 bioDAO.ai